Evidence map›Paper›PMID 31826911›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020

Phytoestrogens and Thyroid Cancer Risk: A Population-Based Case-Control Study in Connecticut.

Qian Wang, Huang Huang, Nan Zhao, Xin Ni, Robert Udelsman, Yawei Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qian WangDivision of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Huang HuangDepartment of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, Connecticut.ORCID 0000-0003-0147-9650
Nan ZhaoCentral Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Xin NiBeijing Children's Hospital, Capital Medical University, Beijing, China.
Robert UdelsmanEndocrine Neoplasm Institute, Miami Cancer Institute, Miami, Florida.
Yawei ZhangDepartment of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven, Connecticut. yawei.zhang@yale.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
PHAHs and Thyroid Cancer Risk in DoDSR CohortR01ES020361 · NIEHS · YALE UNIVERSITY · PI RUSIECKI, JENNIFER ANN, ZHANG, YAWEI · 2012 to 2016
$3.3M
NCATS NIH HHS UL1 TR001863NIEHS NIH HHS R01 ES020361
6 · The paper itself

Abstract

backgroundVery few previous studies have examined the relationship between thyroid cancer risk and intake of phytoestrogens (PE); furthermore, these studies have reached inconsistent results.

methodsWe analyzed data from a population-based case-control study in Connecticut from 2010 to 2011, including 387 histologically confirmed thyroid cancer cases and 433 population-based controls, with compound data available concerning specific PEs. Multivariate unconditional logistic regression models were used to estimate the associations between specific PEs and the risk of thyroid cancer, adjusting for potential confounders.

resultsAn elevated risk of thyroid cancer was associated with moderate to high levels of coumestrol intake [OR = 2.48, 95% confidence interval (CI), 1.39-4.43 for 40-80 μg/day; OR = 2.41, 95% CI, 1.32-4.40 for 80-130 μg/day; and OR = 2.38, 95% CI, 1.26-4.50 for >200 μg/day compared with <40 μg/day], and the main elevation in risk appeared among microcarcinomas (≤1 cm). A decreased risk of papillary macrocarcinomas (>1 cm; OR = 0.26, 95% CI, 0.08-0.85 for 1,860-3,110 μg/day compared with <760 μg/day) was associated with moderate genistein intake among women.

conclusionsOur study suggests that high coumestrol intake increases the risk of thyroid cancer, especially microcarcinomas, whereas moderate amounts of genistein intake appear to be protective for females with thyroid macrocarcinomas. IMPACT: The study highlights the importance of distinguishing between microcarcinomas and macrocarcinomas in future research on the etiology of thyroid cancer.

Indexed as

Feeding BehaviorAdultAgedAged, 80 and overCase-Control StudiesConnecticutCoumestrolDiet SurveysFemaleGenisteinHumansMaleMiddle AgedPhytoestrogensProtective FactorsRisk FactorsCoumestrolGenisteinPhytoestrogens

Identifiers

PMID31826911
PMCPMC7007342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.